Answers are grounded in this paper and cite their sources.
Background Tryptophan metabolism drives colorectal cancer (CRC) pathogenesis through three interconnected cascades: the kynurenine pathway, the serotonin pathway, and the gut‐microbiota‐dominated indole pathway. These pathways exert context‐dependent dual activities determined by disease stage, metabolite concentration, cell type and tumor microenvironment. Substrate competition and metabolic flux redistribution occur across the three branches, while extra‐intestinal tryptophan metabolites mediate multi‐organ crosstalk. Despite substantial preclinical findings, clinical translation is hindered by imperfect predictive biomarkers, therapeutic bypass resistance and insufficient causal evidence for the microbiota‐metabolite‐host axis. Main body This review summarizes biotransformation features and substrate‐competing networks of tryptophan metabolism. The kynurenine pathway, responsible for approximately 95% of systemic tryptophan catabolism, exerts stage‐dependent dual roles. Its plasma‐ and feces‐derived metabolites and rate‐limiting enzyme indoleamine 2,3‐dioxygenase 1 show diagnostic and prognostic potential, yet monotherapies targeting this enzyme yield poor outcomes due to interleukin‐4‐induced gene 1‐mediated bypass resistance. The serotonin pathway accounts for only 1%‐2% of tryptophan flux; it is predominantly tumor‐promoting and protective solely in early‐phase colitis‐associated tumorigenesis. Selective serotonin reuptake inhibitors hold promise for chemoprevention and immunotherapy sensitization. The microbiota‐governed indole pathway generates diverse compounds: indole‐3‐lactic acid, indole‐3‐acetic acid and indole‐3‐propionic acid boost programmed cell death protein 1 (PD‐1)‐based therapeutic efficacy; indole‐3‐acrylic acid and 3‐methylindole facilitate tumor progression; indole‐3‐acetaldehyde displays concentration‐dependent bidirectional effects. We also discuss natural‐product‐based and microbiota‐targeted interventions, as well as key experimental bottlenecks. Conclusion Preclinical metabolite‐guided personalized therapy for CRC requires multi‐omics, stable‐isotope tracing and organoid‐based large‐scale prospective cohorts. Standardized patient stratification and clarification of causal metabolic networks are urgently needed.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: